FebriDx
FebriDx® Can Reduce Unnecessary Antibiotics and Risks
UNNECESSARY USE OF ANTIBIOTICS
LEADS TO ANTIBIOTIC RESISTANCE,
CAUSING MORE THAN

700,000 DEATHS

GLOBALLY1
ANTIBIOTIC RESISTANCE
RESULTS IN COSTS
OVER
$30
BILLION
IN THE U.S. EACH YEAR2

Acute Respiratory Infections and Antibiotics

Acute respiratory infections, producing symptoms such as cough, sore throat, runny nose and congestion, are the most common reason patients seek care worldwide.2-4 The majority of acute respiratory infections are

caused by viruses—in which antibiotics provide no clinical benefit—however the overlapping symptoms make it challenging to differentiate bacterial from viral infections.2

Antibiotics are prescribed
in up to 58% of acute respiratory infection
cases and only required in approximately 11%.5-6

Implications of Unnecessary Antibiotic Use

There are more than 23 million antibiotic prescriptions dispensed in Canada each year, however up to 50% are unnecessary.7-8 Unnecessary antibiotic use leads to increased antibiotic resistance, drug-related adverse events

and increased costs.9 Approximately 20% of drug-related emergency department visits are due to adverse events from antibiotic use, and about 1 in 1,000 has a serious adverse event.10

Antibiotic Adverse Events
adverse effects from antibiotic overuse.

Antibiotics are prescribed in up to 58% of acute respiratory infection cases and only required in approximately 11%.5-6 Knowing whether your patient has a viral or bacterial infection could have a direct impact on the spread of resistant bacteria. FebriDx can make this distinction during the patient visit, offering rapid, point-of-care results.

FebriDx produces a tangible test result that can be shared with the patient, thereby improving patient satisfaction and confidence in their treatment recommendations. With a 97-99% Negative Predictive Value,11 FebriDx can help clinicians rule out a bacterial infection and prevent inappropriate antibiotic prescriptions.

Febridx Cartridge
•FebriDx is not intended to diagnose any specific bacteria or virus, including SARS-CoV-2.
•The test is intended for professional use and should be used in conjunction with other clinical evidence including laboratory, radiographic, and epidemiological information.
•Negative results do not preclude respiratory infection and should not be used as the sole basis for diagnosis, treatment, or other clinical and patient management decisions. In addition to utilizing radiography and clinical presentation to aid in diagnosis, additional laboratory testing (e.g., bacterial and viral culture, immunofluorescence, and polymerase chain reaction [PCR]) may be used to confirm the presence of a specific respiratory pathogen.
1. O’Neill J, et al. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations; The Review on Antimicrobial Resistance: London, UK, 2014.
2. Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults. Ann Intern Med. 2016;165(9):674.
3. Renati S, Linder J. Necessity of office visits for acute respiratory infections in primary care. Fam Pract 2016;33(3):312-17.
4. https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2018-namcs-web-tables-508.pdf
5. Dick K, Schneider J. Economic Evaluation of FebriDx®: A novel rapid, point-of-care test for differentiation of viral versus bacterial acute respiratory infection in the United States. JHEOR 2021;8(2)68-74.
6. Palms DL, Hicks LA, Bartoces M, et al. Comparison of antibiotic prescribing in retail clinics, urgent care centers, emergency departments, and traditional ambulatory care settings in the United States. JAMA Intern Med 2018;178(9):1267-9.
7. https://www.canada.ca/en/public-health/services/publications/drugs-health-products/canadian-antimicrobial-resistance-surveillance-system-report-2016.html
8. https://choosingwiselycanada.org/campaign/antibiotics/
9. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf 2014;5(6): 229-41.
10. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008;47:735-43.
11. Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med 2018;50(5):420-9.